The company intends to allocate the net proceeds toward working capital, specifically targeting research, clinical development, and commercialization efforts. A primary objective of this funding is to support the ongoing advancement of bempikibart, an anti-IL-7Rα antibody currently in Phase 2 trials for the treatment of alopecia areata.
Q32 Bio Launches $200 Million Stock Offering to Fund Autoimmune Research
Waltham-based Q32 Bio has initiated a $200 million public offering of common stock and pre-funded warrants, aiming to bolster its clinical pipeline. The biotechnology firm, which specializes in therapies for alopecia areata, is also granting underwriters an option to purchase an additional $30 million in shares.
Morgan Stanley, Jefferies, and Cantor are serving as joint book-running managers for the transaction. The offering is being conducted under a shelf registration statement declared effective by the SEC on July 13, 2026. Final terms and the completion of the sale remain subject to prevailing market conditions.
/nginx/o/2024/07/18/16228922t1h8f8f.jpg)
Comments (0)
No comments yet. Be the first!